The prognostic value of HSPH1 interaction protein was consistent in both subtypes, suggesting its potential as a pan-NSCLC biomarker, while DNAJB4 may be used as a co-marker of LUAD. This evidence concerns the gene DNAJB4 and non-small cell lung carcinoma.